prikaz prve stranice dokumenta Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment
  Preuzmi
PDF 1.59 MB
diplomski rad
Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment
Split: Sveučilište u Splitu, Medicinski fakultet, 2021. urn:nbn:hr:171:067672
Lange, Matthias
Sveučilište u Splitu
Medicinski fakultet
Medicinska kemija i biokemija

Institucijski repozitorij: Repozitorij MEFST

Citirajte ovaj rad

Lange, M. (2021). Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment (Diplomski rad). Split: Sveučilište u Splitu, Medicinski fakultet. Preuzeto s https://urn.nsk.hr/urn:nbn:hr:171:067672

Lange, Matthias. "Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment." Diplomski rad, Sveučilište u Splitu, Medicinski fakultet, 2021. https://urn.nsk.hr/urn:nbn:hr:171:067672

Lange, Matthias. "Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment." Diplomski rad, Sveučilište u Splitu, Medicinski fakultet, 2021. https://urn.nsk.hr/urn:nbn:hr:171:067672

Lange, M. (2021). 'Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment', Diplomski rad, Sveučilište u Splitu, Medicinski fakultet, citirano: 28.11.2024., https://urn.nsk.hr/urn:nbn:hr:171:067672

Lange M. Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment [Diplomski rad]. Split: Sveučilište u Splitu, Medicinski fakultet; 2021 [pristupljeno 28.11.2024.] Dostupno na: https://urn.nsk.hr/urn:nbn:hr:171:067672

M. Lange, "Distinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment", Diplomski rad, Sveučilište u Splitu, Medicinski fakultet, Split, 2021. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:171:067672

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:171:067672
Podaci o radu
NaslovDistinct GD3 expression in breast cancer subpopulations after novel thieno[2,3-b]pyridine derivative treatment
Naslov (hrvatski)Izrazita ekspresija GD3 u subpopulacijama raka dojke nakon liječenja novim derivatom tieno[2,3-b]piridina
AutorMatthias Lange
MentorVedrana Čikeš Čulić (mentor)
Član povjerenstvaAnita Markotić (predsjednik povjerenstva)
Član povjerenstvaNikolina Režić Mužinić (član povjerenstva)
Član povjerenstvaRenata Pecotić (član povjerenstva)
Ustanova koja je dodijelila
akademski / stručni stupanj		Sveučilište u Splitu
Medicinski fakultet
(Medicinska kemija i biokemija)
Split
Datum i država obrane2021-07-16, Hrvatska
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Medicinska biokemija
Sažetak
Objectives: The goal of this study was to determine GD3 expression after treatment with the novel thieno[2,3-b]pyridine derivative, by focusing on CD44+/CD24- CSCs, CD44- epithelial cells, as well as CD44+/ CD24+ hybrid cells. Methods: The MDA-MB-231 cell line was treated with 3-amino-N-(3-chloro-2- methylphenyl)-5-oxo-5,6,7,8-tetrahydrothieno[2,3-b]quinoline-2-carboxamide (compound 1). Cells were plated onto six-well plates and treated with 2 M compound 1 for 48 h. Following this, cells were stained with anti-GD3, anti-CD44 and anti-CD24 antibodies, and then analyzed via flow cytometry. The acquisition of data of triple-stained samples was done by a BD Accuri C6 cytometer (BD Biosciences) and analyzed with the FlowLogic Software. Results: Treatment of MDA-MB-231 cells with compound 1 has led to a reduction of the expression of GD3 in CD44+/CD24- CSCs, as well as CD44- epithelial cells. GD3 expression in CD44+/CD24+ hybrid cells was not significantly reduced. Conclusion: Due to its ability to reduce GD3 expression in different breast cancer subpopulations, compound 1 has a potential to be used in the treatment of triple-negative breast cancer.
Sažetak (hrvatski)
Ciljevi: Cilj ove studije bio je utvrditi ekspresiju GD3 nakon tretmana novim derivatom tieno[2,3-b]piridina, posebice na CD44+/CD24- matičnim stanicama raka (CSC), CD44- epitelnim stanicama, kao i CD44+/CD24+ hibridnim stanicama. Metode: Stanična linija MDA-MB-231 tretirana je s 3-amino-N-(3-kloro-2-metilfenil)-5- okso-5,6,7,8-tetrahidrotienom[2,3-b]kinolin-2-karboksamid (spoj 1). Stanice su nasađene na ploče sa šest jažica i tretirane s 2 M spojem 1 tijekom 48 sati. Nakon toga, stanice su obojane s protu-GD3, protu-CD44 i protu-CD24 protutijelima, a zatim analizirane protočnom citometrijom. Prikupljanje podataka trostruko obojenih stanica rađeno je citometrom BD Accuri C6 (BD Biosciences) i analizirano softverom FlowLogic. Rezultati: Tretman MDA-MB-231 stanica spojem 1 doveo je do smanjenja ekspresije GD3 na CD44+/CD24- CSC, kao i CD44- epitelnim stanicama. Ekspresija GD3 na hibridnim stanicama CD44+/CD24+ nije bila značajno smanjena. Zaključak: Zbog svoje sposobnosti smanjenja ekspresije GD3 u različitim subpopulacijama raka dojke, spoj 1 ima potencijal za upotrebu u liječenju trostruko-negativnog raka dojke.
Ključne riječi
Ključne riječi (hrvatski)
Jezikengleski
URN:NBNurn:nbn:hr:171:067672
Studijski programNaziv: Medicina na engleskom jeziku
Vrsta studija: sveučilišni
Stupanj studija: integrirani preddiplomski i diplomski
Akademski / stručni naziv: doktor/doktorica medicine (dr. med.)
Vrsta resursaTekst
Način izrade datotekeIzvorno digitalna
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2021-07-19 13:18:46